SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 8-K
Document Type: EX-4.1
Date Filed: 2025-06-12
Accession Number: 0001213900-25-053603
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025053603/ea024541501ex4-1_synergy.htm

Chunk 0 of 8
Word Count: 1497
Character Count: 9345

Document Content:

Exhibit 4.1

PRE-FUNDED COMMON STOCK PURCHASE WARRANT

SYNERGY CHC CORP.

Warrant Shares: 428,570	Initial Issuance Date: June 11, 2025

THIS PRE-FUNDED COMMON STOCK
PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Knight Therapeutics International S.A., a company
registered under the laws of Uruguay, or its assigns (the “Holder”) is entitled, upon the terms and subject to the
limitations on exercise and the conditions hereinafter set forth at any time on or after the date hereof (such date, the “Initial
Exercise Date”) until the earlier of (i) the date and time this Warrant is exercised in full (disregarding the Beneficial Ownership
Limitation) and (ii) 5:00 pm (New York time) on the Termination Date (as defined in Section 2(a)), to subscribe for and purchase from
Synergy CHC Corp., a Nevada corporation (the “Company”), up to 428,570 shares (the “Warrant Shares”)
of common stock, par value $0.00001 per share, of the Company (“Common Stock”), subject to adjustment hereunder. The
purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
This Warrant shall initially be issued and maintained in certificated form.

Section 1. Definitions.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1.

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls, or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

“Alternate
Consideration” shall have the meaning set forth in Section 3(d).

“Attribution
Parties” shall have the meaning set forth in Section 2(e).

“Beneficial Ownership
Limitation” shall have the meaning set forth in Section 2(e).

“Board
of Directors” means the board of directors of the Company.

“Business
Day” means any day other than Saturday, Sunday, or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed.

“Common
Stock” shall have the meaning set forth in the Preamble.

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant, or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

“Company”
shall have the meaning set forth in the Preamble.

“Distribution”
shall have the meaning set forth in Section 3(c).

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

“Exercise
Price” shall have the meaning set forth in Section 2(b).

“Fundamental
Transaction” shall have the meaning set forth in Section 3(d).

“Holder”
shall have the meaning set forth in the Preamble.

“Initial Exercise
Date” shall have the meaning set forth in the Preamble.

“Notice of Exercise”
shall have the meaning set forth in Section 2(a).

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof), or other entity of any kind.

“Purchase
Rights” shall have the meaning set forth in Section 3(b).

“SEC”
means the United States Securities and Exchange Commission.

“Securities
Act” means the Securities Act of 1933 and the rules and regulations promulgated thereunder.

“Subsidiary”
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.

“Successor
Entity” shall have the meaning set forth in Section 3(d).

“Termination Date”
shall have the meaning set forth in Section 2(a).

“Trading
Day” means a day on which the Trading Market is open for trading.

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: The Nasdaq Capital Market, The Nasdaq Global Market, The Nasdaq Global Select Market, the New York Stock Exchange, or the
NYSE American, (or any successors to any of the foregoing).

“Transfer
Agent” means VStock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 18 Lafayette Pl, Woodmere,
NY 11598 and an email address of info@vstocktransfer.com, and any successor transfer agent of the Company.

“Warrant
Register” shall have the meaning set forth in Section 4(c).

“Warrant Share Delivery
Date” shall have the meaning set forth in Section 2(d)(i).

“Warrant Shares”
shall have the meaning set forth in the Preamble.

Section 2. Exercise.

a) Exercise
of Warrant. Subject to the terms and conditions hereof, exercise of the purchase rights represented by this Warrant may be made, in
whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date (as defined below)
by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise
substantially in the form attached hereto as Exhibit A (the “Notice of Exercise”). For purposes of this Warrant, the
term “Termination Date” shall mean June 11, 2026: provided, however, in the event that on or before 5:00 pm (New York
time) on the Termination Date this Warrant has not been exercised in full for all the shares of Common Stock then issuable hereunder due
to the Beneficial Ownership Limitation under Section 2(f), then the exercise period of this Warrant shall be automatically extended by
a period of one year and thereafter (unless the exercise period of this Warrant is automatically extended again pursuant to this sentence)
the Termination Date shall be the next following one year anniversary date of the Termination Date immediately prior to such extension.
Within three (3) Trading Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
number of Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States
bank unless the cashless exercise procedure specified in Section 2(c) below is applicable and specified in the attached Notice of Exercise.
The Company shall have no obligation to inquire with respect to or otherwise confirm the authenticity of the signature(s) contained on
any Notice of Exercise nor the authority of the person so executing such Notice of Exercise. No ink-original Notice of Exercise shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder
has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise
is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares
available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading
Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the
provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.

b) Exercise
Price. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.00001 per Warrant Share, was pre-funded
to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise
price of $0.00001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant.
The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance
or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date. The remaining
unpaid exercise price per share of Common Stock under this Warrant shall be $0.0001, subject to adjustment hereunder (the “Exercise
Price”).

c) Cashless
Exercise. This Warrant may be exercised, in whole or in part, at such time by means of a “cashless exercise” in which
the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where: